Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
International Journal of Molecular Medicine
Join Editorial Board Propose a Special Issue
Print ISSN: 1107-3756 Online ISSN: 1791-244X
Journal Cover
October 2013 Volume 32 Issue 4

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
October 2013 Volume 32 Issue 4

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Ethanol extract of Cnidium officinale exhibits anti-inflammatory effects in BV2 microglial cells by suppressing NF-κB nuclear translocation and the activation of the PI3K/Akt signaling pathway

  • Authors:
    • Shin Hwa Lee
    • Jun Hyuk Lee
    • Eun Young Oh
    • Gi-Young Kim
    • Byung Tae Choi
    • Cheolmin Kim
    • Yung Hyun Choi
  • View Affiliations / Copyright

    Affiliations: Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon 305-701, Republic of Korea, Biotechnology Examination Division, Chemistry and Biotechnology Examination Bureau, Korean Intellectual Property Office, Daejeon 302-701, Republic of Korea, Division of Meridian and Structural Medicine, School of Korean Medicine, Busan National University, Yangsan 626-870, Republic of Korea, Laboratory of Immunobiology, Department of Marine Life Sciences, Jeju National University, Jeju 690-756, Republic of Korea, Research Center for Anti-Aging Technology Development, Busan National University, Busan 609-735, Republic of Korea, Department of Biochemistry, Dongeui University College of Oriental Medicine, Busan 614-052, Republic of Korea
  • Pages: 876-882
    |
    Published online on: July 16, 2013
       https://doi.org/10.3892/ijmm.2013.1447
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Chronic microglial activation endangers neuronal survival through the release of various toxic pro-inflammatory molecules; thus, negative regulators of microglial activation have been identified as potential therapeutic candidates for several neurological diseases. In this study, we investigated the inhibitory effects of an ethanol extract of Cnidium officinale rhizomes (EECO), which has been used as a herbal drug in Oriental medicine, on the production of lipopolysaccharide (LPS)-induced pro-inflammatory mediators, such as nitric oxide (NO) and prostaglandin E2 (PGE2), as well as that of pro-inflammatory cytokines in BV2 microglia cells. EECO significantly inhibited the excess production of NO and PGE2 in LPS-stimulated BV2 microglia cells. It also attenuated the expression of inducible NO synthase, cyclooxygenase-2, as well as that of pro-inflammatory cytokines, such as interleukin-1β and tumor necrosis factor-α. Moreover, EECO exhibited anti-inflammatory properties by suppressing nuclear factor-κB (NF-κB) translocation and the activation of the phosphoinositide 3-kinase/Akt pathway in LPS-stimulated BV2 cells. These results indicate that EECO exerts anti-inflammatory effects in LPS-stimulated BV2 microglial cells by inhibiting pro-inflammatory mediators and cytokine production by blocking the NF-κB pathway. These findings suggest that EECO has substantial therapeutic potential for the treatment of neurodegenerative diseases accompanied by microglial activation.

Introduction

Microglia are important cells that are involved in initial responses to tissue damage in the central nervous system (CNS). However, abnormally overactivated microglia promote the expression of pro-inflammatory mediators, such as nitric oxide (NO) and prostaglandin E2 (PGE2), as well as that of pro-inflammatory cytokines, including interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) and monocyte chemoattractant protein-1 and other factors that contribute to the development of chronic inflammatory diseases (1–3). In particular, microglia are activated by lipopolysaccharides (LPS), β-amyloid, thrombin, or interferon-γ, and the secretion of inflammatory molecules by abnormally activated microglia disturbs the homeostasis of the immune system, thus inducing and promoting degenerative CNS autoimmune diseases, such as multiple sclerosis, Alzheimer’s disease and Parkinsonism (4–6). Therefore, understanding congenital immune system disorders related to the overactivation of microglia and controlling the inflammation molecules secreted by abnormally activated microglia is an approach to delaying chronic inflammatory diseases.

The transcription factor, nuclear factor-κB (NF-κB), plays a central role in the regulation of several genes responsible for the generation of pro-inflammatory mediators and cytokines. In normal cells, NF-κB subunits are present in the cytosol bound to the inhibitory protein IκB (IκB), which inactivates them (7,8). However, in response to various stimuli, such as LPS, IκB is rapidly degraded by the ubiquitin-proteasome pathway. The degradation of IκB induces the translocation of NF-κB subunits into the nucleus, and the NF-κB subunits bind to the promoter regions of target genes, including inducible NO synthase (iNOS), cyclooxygenase-2 (COX-2), TNF-α and IL-1β, and stimulate their transcription. The activation of the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway plays an important role in regulating LPS-induced pro-inflammatory responses by inducing NF-κB activation through proteasome-dependent IκB degradation (9–14). Therefore, inhibiting NF-κB activation through the PI3K/Akt pathway results in anti-inflammatory effects.

Cnidium officinale (C. officinale) Makino, which belongs to the Umbelliferae family, is a perennial herb native to China. The dried rhizomes of C. officinale have been used as one of the most commonly prescribed traditional Oriental medicinal herbs in East Asian countries. In Korean traditional medicine, they are widely used in the treatment of menstrual disturbances and as a blood pressure depressant, as well as for relieving pain from headaches and rheumatic arthralgia (15–20). Although some pharmacological beneficial effects of this herb and extracts of its rhizome have recently been reported, including anticancer, anti-inflammatory and antioxidant effects (21–24), its molecular mechanisms of action have not yet been fully elucidated. Therefore, the present study was conducted to evaluate the effects of an ethanol extract of C. officinale rhizomes (EECO) on the production of pro-inflammatory mediators and cytokines and the respective regulatory genes with a focus on the underlying molecular mechanisms in LPS-stimulated BV2 microglial cells.

Materials and methods

Reagents, chemicals and preparation of EECO

LPS and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Antibodies against COX-2, iNOS, TNF-α, IL-1β, NF-κB p65 and IκB-α were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Antibodies against phosphorylated PI3K (p-PI3K), PI3K, phosphorylated Akt (p-Akt) and Akt were obtained from Cell Signaling Technology (Beverly, MA, USA). Antibodies against nucleolin and actin were obtained from Sigma-Aldrich. Peroxidase-labeled goat anti-rabbit immunoglobulin was purchased from Koma Biotechnology (Seoul, Korea). Other chemicals were purchased from Sigma-Aldrich. To prepare EECO, the rhizomes of C. officinale, which were obtained from Dongeui University Oriental Hospital (Busan, Korea), were pulverized and extracted twice with 10 volumes of 80% ethanol at 85–90°C in a reflux condenser for 3 h, and then filtered with a 50 μm filter and concentrated by vacuum evaporation at 60°C. The solid form of the extract was dissolved in dimethyl sulfoxide.

Cell culture and viability assay

BV2 microglial cells were cultured at 37°C in 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 5% fetal bovine serum and antibiotics (WelGENE Inc., Daegu, Korea). In all the experiments, the cells were pre-treated with the indicated concentrations of EECO for 1 h prior to the addition of LPS (500 ng/ml) in serum-free DMEM. Cell viability was measured based on the formation of blue formazan that was metabolized from colorless MTT by mitochondrial dehydrogenases, which are active only in live cells. In brief, the BV2 cells were seeded and treated with reagents for the indicated periods of time. Following treatment, the medium was removed, and the cells were incubated with 0.5 mg/ml of MTT solution for 2 h at 37°C and 5% CO2, and then the supernatant was removed and the formation of formazan was measured at 540 nm using a microplate reader (Dynatech MR-7000; Dynatech Laboratories, Chantilly, VA, USA).

Measurement of NO

The concentration of NO generated by BV2 cells activated by LPS was detected using Griess reagent [1% sulfanilamide in 5% phosphoric acid and 0.1% N-(1-naphthyl)ethylenediamine dihydrochloride]. BV2 cells were cultured for 24 h in a 6-well culture plate, pre-treated with various concentrations of EECO for 1 h, and then treated again with LPS (500 ng/ml). After 24 h of culture, the cell culture medium was collected and the same quantity of Griess reagent was added to induce a reaction at room temperature. The optical density of the reaction solution was measured at 540 nm using a microplate reader and the quantity of NO generated by the cells was calculated based on the concentration of the sodium nitrite (NaNO2) standard solution (standard curve).

Measurement of PGE2

To measure the quantity of PGE2 generated by BV2 cells, medium from the cultures under the same conditions was collected and the quantity of PGE2 generated was measured using a PGE2 enzyme-linked immunosorbent assay (ELISA) kit (Cayman Chemical Co., Ann Arbor, MI, USA). The concentration (pg/ml) of PGE2 in the cell culture medium was calculated based on the concentrations of the standard solution as previously described (25).

Measurement of cytokines

The levels of IL-1β and TNF-α were measured using ELISA kits (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions. Briefly, BV2 cells were loaded in 24-well plates and pre-treated with the indicated EECO concentrations for 1 h prior to stimulation with 500 ng/ml LPS for 24 h. A total of 100 μl of culture medium supernatant was collected to determine IL-1β and TNF-α concentration by ELISA.

Isolation of total RNA and reverse transcription-polymerase chain reaction (RT-PCR)

RT-PCR was conducted to examine the effects of EECO on the expression of LPS-induced iNOS, COX-2, and inflammatory cytokines at the transcription level. Total RNA was separated from the BV2 cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions and reverse-transcribed using MMLV reverse transcriptase (Promega, Madison, WI, USA) to produce cDNA. The cDNA was amplified by PCR using specific primers: iNOS forward, 5′-CCT CCT CCA CCC TAC CAA GT-3′ and reverse, 5′-CAC CCA AAG TGC TTC AGT CA-3′; COX-2 forward, 5′-AAG ACT TGC CAG GCT GAA CT-3′ and reverse, 5′-CTT CTG CAG TCC AGG TTC AA-3′; IL-1β forward, 5′-ATG GCA ACT GTT CCT GAA CTC AAC T-3′ and reverse, 5′-TTT CCT TTC TTA GAT ATG GAC AGG AC-3′; TNF-α forward, 5′-GCG ACG TGG AAC TGG CAG AA-3′ and reverse, 5′-TCC ATG CCG TTG GCC AGG AG-3′; and GAPDH forward, 5′-ACC ACA GTC CAT GCC ATC AC-3′ and reverse, 5′-TCC ACC ACC CTG TTG CTG TA-3′. The following PCR conditions were applied: iNOS, COX-2, IL-1β and TNF-α: 25 cycles of denaturation at 94°C for 30 sec, annealing at 59°C for 30 sec, and extension at 72°C for 30 sec; GAPDH, 23 cycles of denaturation at 94°C for 30 sec, annealing at 57°C for 30 sec and extension at 72°C for 30 sec. The PCR products were electrophoresed on 1.5% agarose gels and stained with ethidium bromide. GAPDH was used as an internal control to evaluate relative expression.

Protein extraction and western blot analysis

The cells were washed three times with phosphate-buffered saline (PBS) and lysed in lysis buffer [1% Triton X-100, 1% deoxycholate, 0.1% sodium azide (NaN3)] containing protease inhibitor cocktail tablets to isolate total protein (Roche Diagnostics GmbH, Mannheim, Germany). In a parallel experiment, cytoplasmic and nuclear extracts were prepared using NE-PER nuclear and cytosolic extraction reagents (Pierce, Rockford, IL, USA) according to the manufacturer’s instructions. The protein concentrations were determined using a Bio-Rad protein assay kit (Bio-Rad, Hercules, CA, USA). Equal amounts of protein were separated on SDS-polyacrylamide gels and transferred onto nitrocellulose membranes (Schleicher & Schuell, Inc., Keene, NH, USA) by electroblotting. Proteins were detected using an enhanced chemiluminescence detection system (Pierce).

Immunofluorescence

The prepared cells were washed twice with PBS and fixed for 15 min at 4°C using 4% paraformaldehyde. The cells were washed again with PBS, reactions were induced for 20 min at 4°C in PBS that contained 0.3% Triton X-100, and then reactions were induced for 1 h at room temperature in PBS containing 2% bovine serum albumin (BSA) to suppress non-specific reactions. The anti-NF-κB p65 antibody was then diluted to 1:200 in a PBS solution that contained 2% BSA to induce reactions for 2 h at room temperature. The cells were washed three times in PBS and fluorescein isothiocyanate (FITC)-conjugated IgG (Molecular Probes, Eugene, OR, USA), which is a secondary antibody, was diluted to 1:100 to induce reactions for 1 h at room temperature. Samples of the immunofluorescence-stained cells were observed under a confocal laser scanning microscope (Olympus, Tokyo, Japan). A wavelength of 488 nm was used for FITC, and the images were reassembled into final three-dimensional images according to the manufacturer’s instructions (Olympus Fluoview 300, Olympus).

Statistical analysis

All results are expressed as the means ± standard errors. Each experiment was repeated at least three times. Statistical significances were identified between each treated group by the paired Student’s t-test. A P-value <0.05 was considered to indicate a statistically significant difference.

Results

Inhibition of LPS-induced NO and PGE2 production by EECO

To determine the inhibitory effects of EECO on LPS-induced NO and PGE2 production, BV2 macroglial cells were incubated with the indicated concentrations of EECO in the presence or absence of LPS for 24 h, and the levels of NO and PGE2 production were measured in the culture medium using Griess reagent and ELISA, respectively. LPS triggered an approximate 7-fold increase in NO production compared with that in the untreated control group; however, pre-treatment with EECO reduced LPS-induced NO production in a concentration-dependent manner (Fig. 1A). The amount of PGE2 present in the culture medium also increased after 24 h of exposure to LPS alone; however, a concentration-dependent decrease was observed following pre-treatment with EECO (Fig. 1B).

Figure 1

Inhibition of nitric oxide (NO) and prostaglandin E2 (PGE2) production by the ethanol extract of Cnidium officinale rhizomes (EECO) in lipopolysaccharide (LPS)-stimulated BV2 microglia cells. BV2 cells were pre-treated with various concentrations of EECO (12.5–100 μg/ml) for 1 h prior to incubation with LPS (500 ng/ml) for 24 h. (A) Nitrite content was measured by Griess reaction and (B) PGE2 concentration was measured in the culture medium using a commercial enzyme-linked immunosorbent assay (ELISA) kit. Each value indicates the mean ± standard deviation of results obtained from three independent experiments. *P<0.05 indicates a significant difference from the value obtained for cells treated with LPS in the absence of EECO.

Inhibition of LPS-induced NO and PGE2 expression by EECO

We then investigated whether the inhibitory effects of EECO on NO and PGE2 production are associated with decreased levels of iNOS and COX-2 expression, which are known to induce NO and PGE2 production, using western blot analysis and RT-PCR. The mRNA levels of iNOS and COX-2 were markedly augmented in the presence of LPS alone; however, their expression levels were markedly upregulated in the presence of EECO (Fig. 2A). Western blot analyses also revealed that treatment with LPS increased iNOS and COX-2 protein expression, whereas pre-treatment of the cells with EECO attenuated the LPS-induced iNOS and COX-2 protein expression (Fig. 3B). These results indicate that EECO inhibits the LPS-induced release of NO and PGE2 by suppressing iNOS and COX-2 expression at the transcriptional level.

Figure 2

Inhibition of inducible nitric oxide (NO) synthase (iNOS) and cyclooxygenase-2 (COX-2) expression by the ethanol extract of Cnidium officinale rhizomes (EECO) in lipopolysaccharide (LPS)-stimulated BV2 microglial cells. (A) BV2 cells were treated with 100 μg/ml EECO or 500 ng/ml LPS alone, or pre-treated with 100 μg/ml EECO for 1 h prior to treatment with LPS. Following treatment with LPS for 6 h, total RNA was prepared for RT-PCR analysis of iNOS and COX-2 mRNA expression in LPS-stimulated BV2 microglial cells. (B) Cells were pre-treated with EECO 1 h prior to incubation with LPS (500 ng/ml) for 24 h. The cells were then lysed and the same amounts of cellular proteins were separated on SDS-polyacrylamide gels. After the proteins were transferred onto nitrocellulose membranes, the membranes were probed with anti-iNOS and anti-COX-2 antibodies. The proteins were visualized using an ECL detection system. GAPDH and actin were used as internal controls for the RT-PCR and western blot assays, respectively.

Figure 3

Effect of the ethanol extract of Cnidium officinale rhizomes (EECO) on lipopolysaccharide (LPS)-stimulated tumor necrosis factor-α (TNF-α) and interleukin (IL)-1β production in BV2 microglia cells. BV2 cells were pre-treated with various concentrations of EECO for 1 h prior to treatment with 500 ng/ml LPS. After 2 h of incubation, the levels of (A) TNF-α and (B) IL-1β present in the supernatants were measured using enzyme-linked immunosorbent assay (ELISA). Each value indicates the mean ± standard deviation of results obtained from three independent experiments. *P<0.05 indicates a significant difference from the value obtained for the cells treated with LPS in the absence of EECO.

Inhibition of LPS-induced TNF-α and IL-1β generation by EECO

We then determined the potential effects of EECO on the production of pro-inflammatory cytokines, such as TNF-α and IL-1β by ELISA. The levels of TNF-α significantly increased in the culture medium of LPS-stimulated BV2 cells; however, the levels decreased significantly in a dose-dependent manner following pre-treatment with EECO (Fig. 3A). IL-1β production increased following stimulation with LPS and EECO significantly decreased the levels of IL-1β in the supernatant of LPS-stimulated BV2 cells (Fig. 3B).

Inhibition of LPS-induced TNF-α and IL-1β expression by EECO

RT-PCR and western blot analysis were performed in parallel experiments to determine whether EECO inhibits TNF-α and IL-1β expression. The increased expression of TNF-α and IL-1β following treatment with LPS was markedly attenuated by pre-treatment with EECO at both the transcriptional and translational levels (Fig. 4). These results indicate that EECO is effective in suppressing pro-inflammatory cytokine production by altering the transcriptional levels of TNF-α and IL-1β in LPS-activated microglia.

Figure 4

Inhibition of tumor necrosis factor-α (TNF-α) and interleukin (IL)-1β expression by ethanol extract of Cnidium officinale rhizomes (EECO) in lipopolysaccharide (LPS)-stimulated BV2 microglia cells. (A) BV2 cells were treated with 100 μg/ml EECO or 500 ng/ml LPS alone, or pre-treated with 100 μg/ml EECO for 1 h prior to treatment with LPS. Following treatment with LPS for 6 h, total RNA was prepared for RT-PCR analysis of TNF-α and IL-1β mRNA expression in LPS-stimulated BV2 microglial cells. (B) Cells were pre-treated with EECO 1 h prior to incubation with LPS (500 ng/ml) for 24 h. The cells were then lysed and the same amounts of cellular proteins were separated on SDS-polyacrylamide gels. After the proteins were transferred onto nitrocellulose membranes, the membranes were probed with anti-TNF-α and anti-IL-1β antibodies. The proteins were visualized using an ECL detection system. GAPDH and actin were used as internal controls for the RT-PCR and western blot assays, respectively.

Inhibition of LPS-induced NF-κB translocation by EECO

As NF-κB is a central transcription factor that regulates the expression of a large number of inflammation-related genes (7,26), the effects of EECO on the LPS-stimulated nuclear translocation of NF-κB p65 subunits were examined. The western blot analysis results in Fig. 5A indicate that the levels of NF-κB p65 in the nucleus markedly increased within 15 min of exposure to LPS; however, the LPS-induced p65 levels in the nuclear fraction decreased following pre-treatment with EECO. In addition, IκB-α was markedly degraded 15 min following exposure to LPS; however, the LPS-induced IκB-α degradation was significantly reversed by EECO. We also investigated whether EECO interferes with the translocation of NF-κB in LPS-treated BV2 cells by immunofluorescence. The level of NF-κB p65 in the nucleus decreased significantly by EECO, indicating that EECO inhibits NF-κB activation in BV2 microglial cells by suppressing IκB degradation and the nuclear translocation of NF-κB (Fig. 4B).

Figure 5

Effects of the ethanol extract of Cnidium officinale rhizomes (EECO) on lipopolysaccharide (LPS)-induced nuclear factor-κB (NF-κB) translocation in BV2 microglial cells. (A) Cells were treated with 100 μg/ml EECO for 1 h prior to treatment with 500 ng/ml LPS for the indicated time periods of time. Nuclear and cytosolic proteins were isolated and subjected to 10% SDS-polyacrylamide gel electrophoresis followed by western blot analysis using anti-NF-κB p65 and anti-IκB-α antibodies. Nucleolin was used as the internal control for the nuclear fraction. (B) BV2 cells were pre-treated with EECO for 1 h prior to stimulation with LPS for 1 h. NF-κB p65 protein localization was determined using an anti-NF-κB p65 antibody and an fluorescein isothiocyanate (FITC)-labeled anti-rabbit IgG antibody, and cells were visualized under a laser confocal scanning microscope.

Inhibition of LPS-induced PI3K/Akt activation by EECO

As the activation of the PI3K/Akt signaling pathway leads to the production of inflammatory mediators and cytokines through the activation of NF-κB (9–12), we investigated the effects of EECO on the phosphorylation of PI3K and Akt proteins in LPS-stimulated BV2 cells. Using western blot analysis with anti-phospho-specific antibodies for PI3K and Akt, we found that EECO suppressed the LPS-induced phosphorylation of PI3K and Akt (Fig. 6), whereas the levels of non-phosphorylated PI3K and Akt were unaffected by either EECO or LPS treatment. These findings strongly suggest that the anti-inflammatory effects of EECO in LPS-stimulated BV2 cells are associated with the inactivation of the PI3K/Akt pathway.

Figure 6

Effect of the ethanol extract of Cnidium officinale rhizomes (EECO) on lipopolysaccharide (LPS)-induced phosphorylation of phosphoinositide 3-kinase (PI3K) and Akt in BV2 microglial cells. BV2 cells were pre-treated with 100 μg/ml EECO for 1 h prior to treatment with LPS (500 ng/ml), and total proteins were isolated at the indicated times following treatment with LPS. Proteins were subjected to SDS-polyacrylamide gel electrophoresis followed by western blot analysis using the indicated antibodies, and an ECL detection system.

Effect of EECO on the viability of BV2 microglial cells

We evaluated the viability of BV2 cells incubated with or without LPS in the absence or presence of EECO by MTT assay to determine the cytotoxic effects (if any) of EECO on BV2 microglia. The concentrations (12.5 to 100 μM/ml) of EECO used to inhibit LPS-induced inflammatory responses did not affect cell viability, confirming that the anti-inflammatory effects of EECO in LPS-stimulated BV2 cells are not due to the cytotoxicity of EECO (Fig. 7).

Figure 7

Effects of the ethanol extract of Cnidium officinale rhizomes (EECO) and lipopolysaccharide (LPS) on the viability of BV2 microglia cells. Cells were treated with 100 μg/ml EECO or 500 ng/ml LPS alone, or pre-treated with the indicated concentrations of EECO for 1 h prior to treatment with LPS. After 24 h, cell viability was assessed by MTT reduction assays. Each value indicates the mean ± standard deviation of results obtained from three independent experiments.

Discussion

In the present study, we found that EECO impaired LPS-induced gene expression and the secretion of pro-inflammatory mediators (NO and PGE2), as well as that of the inflammation-related genes, iNOS and COX-2, and cytokines (IL-1β and TNF-α) in a BV2 microglia cell model. Further experiments revealed that EECO attenuated the LPS-induced NF-κB activation by suppressing the degradation of IκB-α, which was associated with the inactivation of the PI3K/Akt signaling pathway.

Inflammation in the brain caused by activated microglia plays an important role in the pathology of neurodegenerative disorders (5,6). iNOS and COX-2, which are responsible for synthesizing NO and PGE2, respectively, are critical enzymes that mediate inflammatory processes. The improper upregulation of iNOS and COX-2 has been associated with certain types of inflammatory disorders, including neuronal degeneration (27,28). Pro-inflammatory cytokines also play critical roles in the process of inflammation and the increased production of these cytokines is associated with neuronal dysfunction and neuronal loss (29,30). Therefore, the suppression of neuroinflammation during microglial activation would theoretically attenuate the progression of neurodegenerative disease. Thus, the inhibition of pro-inflammatory mediators and cytokines by EECO in LPS-stimulated BV2 microglia shown in the present study, may play a beneficial role in the treatment of neurodegenerative diseases.

NF-κB is an important transcription factor that regulates various cellular responses required for inducing the expression of inflammation-related genes (7,26). In an inactive state, NF-κB exists as a heterodimer of p65 and p50 subunits in the cytoplasm, but translocates to the nucleus once activated through the phosphorylation and degradation of IκB, and proceeds to transcribe the majority of pro-inflammatory genes, thus contributing to the development of anaphylaxis, septic shock, multiple organ failure and even cell death (31–33). In our experiments, the majority of intracellular NF-κB p65 had translocated from the cytosol to the nucleus following treatment with LPS, as demonstrated by strong NF-κB p65 accumulation and staining in the nucleus. However, the levels of NF-κB p65 in the nucleus decreased significantly following pre-treatment with EECO. These results suggest that EECO inhibits LPS-induced acute pro-inflammatory responses mediated by the NF-κB signaling pathway.

The PI3K/AKT signaling pathway also controls a variety of cellular proliferation and survival processes. Upon stimulation, PI3K phosphorylates specific phosphoinositide lipids, which accumulate in the plasma membrane, creating docking sites for Akt. Akt undergoes phosphorylation at the plasma membrane, leading to its activation (34,35). Numerous studies have shown that the PI3K/Akt signaling pathway plays an important role in negatively regulating LPS-induced acute inflammatory responses in microglia (13,14,36–38). Although the role of PI3K/Akt signaling cascades in the regulation of NF-κB transactivation remains controversial (8,39,40), certain studies have demonstrated that LPS-induced NF-κB activation is directly regulated as a main upstream molecule of NF-κB via the phosphorylation of Akt (41,42). Therefore, to further confirm the inhibitory effects of NF-κB activation by EECO, we investigated the effects of EECO on the levels of PI3K and Akt phosphorylation in LPS-stimulated BV2 cells. As a result, we found that PI3K and Akt phosphorylation was markedly suppressed by EECO. These results suggest that EECO inhibits LPS-induced NF-κB activation by inhibiting the activation of the PI3K/Akt pathway.

In conclusion, in this study, we demonstrate that EECO inhibits pro-inflammatory mediator and cytokine production by suppressing the activation of NF-κB in LPS-stimulated BV2 microglial cells. The regulation of NF-κB activity by EECO was also associated with the inactivation of the PI3K/Akt signaling pathway during the LPS-induced anti-inflammatory reaction. Therefore, the present results provide a molecular basis for understanding the inhibitory effects of C. officinale rhizomes on endotoxin-mediated inflammation.

Acknowledgements

This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) grant funded by the Korean government (no. 2012046358) and the R&D program of MKE/KEIT (10040391, Development of Functional Food Materials and Device for Prevention of Aging-associated Muscle Function Decrease).

References

1 

Hailer NP: Immunosuppression after traumatic or ischemic CNS damage: it is neuroprotective and illuminates the role of microglial cells. Prog Neurobiol. 84:211–233. 2008. View Article : Google Scholar : PubMed/NCBI

2 

Kriz J: Inflammation in ischemic brain injury: timing is important. Crit Rev Neurobiol. 18:145–157. 2006. View Article : Google Scholar : PubMed/NCBI

3 

Mirshafiey A and Jadidi-Niaragh F: Prostaglandins in pathogenesis and treatment of multiple sclerosis. Immunopharmacol Immunotoxicol. 32:543–554. 2010. View Article : Google Scholar : PubMed/NCBI

4 

Dheen ST, Kaur C and Ling EA: Microglial activation and its implications in the brain diseases. Curr Med Chem. 14:1189–1197. 2007. View Article : Google Scholar : PubMed/NCBI

5 

McGeer PL and McGeer EG: Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging. 22:799–809. 2001. View Article : Google Scholar : PubMed/NCBI

6 

Liu B, Gao HM and Hong JS: Parkinson’s disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect. 111:1065–1073. 2003.

7 

Atreya I, Atreya R and Neurath MF: NF-kappaB in inflammatory bowel disease. J Intern Med. 263:591–596. 2008. View Article : Google Scholar : PubMed/NCBI

8 

Tas SW, Vervoordeldonk MJ and Tak PP: Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer. Curr Gene Ther. 9:160–170. 2009. View Article : Google Scholar

9 

Qi S, Xin Y, Guo Y, Diao Y, Kou X, Luo L and Yin Z: Ampelopsin reduces endotoxic inflammation via repressing ROS-mediated activation of PI3K/Akt/NF-κB signaling pathways. Int Immunopharmacol. 12:278–287. 2012.PubMed/NCBI

10 

Kang CH, Jayasooriya RG, Dilshara MG, Choi YH, Jeong YK, Kim ND and Kim GY: Caffeine suppresses lipopolysaccharide-stimulated BV2 microglial cells by suppressing Akt-mediated NF-κB activation and ERK phosphorylation. Food Chem Toxicol. 50:4270–4276. 2012.PubMed/NCBI

11 

Yasuda T: Hyaluronan inhibits Akt, leading to nuclear factor-κB down-regulation in lipopolysaccharide-stimulated U937 macrophages. J Pharmacol Sci. 115:509–515. 2011.PubMed/NCBI

12 

Chiou WF, Don MJ, Liao JF and Wei BL: Psoralidin inhibits LPS-induced iNOS expression via repressing Syk-mediated activation of PI3K-IKK-IκB signaling pathways. Eur J Pharmacol. 650:102–109. 2011.PubMed/NCBI

13 

Lee HS, Kwon SH, Ham JE, Lee JY, Kim DH, Shin KH and Choi SH: Zaprinast activates MAPKs, NFκB, and Akt and induces the expressions of inflammatory genes in microglia. Int Immunopharmacol. 13:232–241. 2012.PubMed/NCBI

14 

Lee YH, Jeon SH, Kim SH, Kim C, Lee SJ, Koh D, Lim Y, Ha K and Shin SY: A new synthetic chalcone derivative, 2-hydroxy-3′,5,5′-trimethoxychalcone (DK-139), suppresses the Toll-like receptor 4-mediated inflammatory response through inhibition of the Akt/NF-κB pathway in BV2 microglial cells. Exp Mol Med. 44:369–377. 2012.PubMed/NCBI

15 

Bae KE, Choi YW, Kim ST and Kim YK: Components of rhizome extract of Cnidium officinale Makino and their in vitro biological effects. Molecules. 16:8833–8847. 2011.PubMed/NCBI

16 

de Caires S and Steenkamp V: Use of Yokukansan (TJ-54) in the treatment of neurological disorders: a review. Phytother Res. 24:1265–1270. 2010.PubMed/NCBI

17 

Bark KM, Heo EP, Han KD, Kim MB, Lee ST, Gil EM and Kim TH: Evaluation of the phototoxic potential of plants used in oriental medicine. J Ethnopharmacol. 127:11–18. 2010. View Article : Google Scholar : PubMed/NCBI

18 

Jeong SI, Kwak DH, Lee S, Choo YK, Woo WH, Keum KS, Choi BK and Jung KY: Inhibitory effects of Cnidium officinale Makino and Tabanus fulvus Meigan on the high glucose-induced proliferation of glomerular mesangial cells. Phytomedicine. 12:648–655. 2005.

19 

Kwon JH and Ahn YJ: Acaricidal activity of butylidenephthalide identified in Cnidium officinale rhizome against Dermatophagoides farinae and Dermatophagoides pteronyssinus (Acari: Pyroglyphidae). J Agric Food Chem. 50:4479–4483. 2002.PubMed/NCBI

20 

Tomoda M, Ohara N, Shimizu N and Gonda R: Characterization of a novel heteroglucan from the rhizome of Cnidium officinale exhibiting high reticuloendothelial system-potentiating and anti-complementary activities. Biol Pharm Bull. 17:973–976. 1994.PubMed/NCBI

21 

Jeong JB, Ju SY, Park JH, Lee JR, Yun KW, Kwon ST, Lim JH, Chung GY and Jeong HJ: Antioxidant activity in essential oils of Cnidium officinale Makino and Ligusticum chuanxiong Hort and their inhibitory effects on DNA damage and apoptosis induced by ultraviolet B in mammalian cell. Cancer Epidemiol. 33:41–46. 2009.PubMed/NCBI

22 

Jeong JB, Park JH, Lee HK, Ju SY, Hong SC, Lee JR, Chung GY, Lim JH and Jeong HJ: Protective effect of the extracts from Cnidium officinale against oxidative damage induced by hydrogen peroxide via antioxidant effect. Food Chem Toxicol. 47:525–529. 2009.PubMed/NCBI

23 

Kim SJ, Kwon do Y, Kim YS and Kim YC: Peroxyl radical scavenging capacity of extracts and isolated components from selected medicinal plants. Arch Pharm Res. 33:867–873. 2010. View Article : Google Scholar : PubMed/NCBI

24 

Ramalingam M and Yong-Ki P: Free radical scavenging activities of Cnidium officinale Makino and Ligusticum chuanxiong Hort. methanolic extracts. Pharmacogn Mag. 6:323–330. 2010.PubMed/NCBI

25 

Bae DS, Kim YH, Pan CH, Nho CW, Samdan J, Yansan J and Lee JK: Protopine reduces the inflammatory activity of lipopolysaccharide-stimulated murine macrophages. BMB Rep. 5:108–113. 2012.PubMed/NCBI

26 

Tas SW, Remans PH, Reedquist KA and Tak PP: Signal transduction pathways and transcription factors as therapeutic targets in inflammatory disease: towards innovative antirheumatic therapy. Curr Pharm Des. 11:581–611. 2005. View Article : Google Scholar

27 

Shie FS, Montine KS, Breyer RM and Montine TJ: Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia. 52:70–77. 2005. View Article : Google Scholar : PubMed/NCBI

28 

Aid S, Langenbach R and Bosetti F: Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J Neuroinflammation. 5:172008. View Article : Google Scholar : PubMed/NCBI

29 

Leone S, Ottani A and Bertolini A: Dual acting anti-inflammatory drugs. Curr Top Med Chem. 7:265–275. 2007. View Article : Google Scholar

30 

Mariani MM and Kielian T: Microglia in infectious diseases of the central nervous system. J Neuroimmune Pharmacol. 4:448–461. 2009. View Article : Google Scholar : PubMed/NCBI

31 

Murphy K, Haudek SB, Thompson M and Giroir BP: Molecular biology of septic shock. New Horiz. 6:181–193. 1998.

32 

Pushparaj PN, Tay HK, H’ng SC, Pitman N, Xu D, McKenzie A, Liew FY and Melendez AJ: The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA. 106:9773–9778. 2009. View Article : Google Scholar : PubMed/NCBI

33 

Manukyan MC, Weil BR, Wang Y, Abarbanell AM, Herrmann JL, Poynter JA and Meldrum DR: The phosphoinositide-3 kinase survival signaling mechanism in sepsis. Shock. 34:442–449. 2010. View Article : Google Scholar : PubMed/NCBI

34 

Carnero A, Blanco-Aparicio C, Renner O, Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 8:187–198. 2008. View Article : Google Scholar : PubMed/NCBI

35 

Ito K, Caramori G and Adcock IM: Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. J Pharmacol Exp Ther. 321:1–8. 2007. View Article : Google Scholar : PubMed/NCBI

36 

Choi YH and Park HY: Anti-inflammatory effects of spermidine in lipopolysaccharide-stimulated BV2 microglial cells. J Biomed Sci. 19:312012. View Article : Google Scholar : PubMed/NCBI

37 

Park HY, Han MH, Kim GY, Kim ND, Nam TJ and Choi YH: Inhibitory effects of glycoprotein isolated from Laminaria japonica on lipopolysaccharide-induced pro-inflammatory mediators in BV2 microglial cells. J Food Sci. 76:T156–T162. 2011. View Article : Google Scholar

38 

Park HY, Kim GY and Choi YH: Naringenin attenuates the release of pro-inflammatory mediators from lipopolysaccharide-stimulated BV2 microglia by inactivating nuclear factor-κB and inhibiting mitogen-activated protein kinases. Int J Mol Med. 30:204–210. 2012.PubMed/NCBI

39 

Takeshima E, Tomimori K, Kawakami H, Ishikawa C, Sawada S, Tomita M, Senba M, Kinjo F, Mimuro H, Sasakawa C, Fujita J and Mori N: NF-kappaB activation by Helicobacter pylori requires Akt-mediated phosphorylation of p65. BMC Microbiol. 9:362009.

40 

Wei J and Feng J: Signaling pathways associated with inflammatory bowel disease. Recent Pat Inflamm Allergy Drug Discov. 4:105–117. 2010. View Article : Google Scholar : PubMed/NCBI

41 

Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP and Baldwin AS: Akt-dependent regulation of NF-kappaB is controlled by mTOR and Raptor in association with IKK. Genes Dev. 22:1490–1500. 2008. View Article : Google Scholar : PubMed/NCBI

42 

Minhajuddin M, Bijli KM, Fazal F, Sassano A, Nakayama KI, Hay N, Platanias LC and Rahman A: Protein kinase C-delta and phosphatidylinositol 3-kinase/Akt activate mammalian target of rapamycin to modulate NF-kappaB activation and intercellular adhesion molecule-1 (ICAM-1) expression in endothelial cells. J Biol Chem. 284:4052–4061. 2009. View Article : Google Scholar

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Lee SH, Lee JH, Oh EY, Kim G, Choi BT, Kim C and Choi YH: Ethanol extract of Cnidium officinale exhibits anti-inflammatory effects in BV2 microglial cells by suppressing NF-κB nuclear translocation and the activation of the PI3K/Akt signaling pathway. Int J Mol Med 32: 876-882, 2013.
APA
Lee, S.H., Lee, J.H., Oh, E.Y., Kim, G., Choi, B.T., Kim, C., & Choi, Y.H. (2013). Ethanol extract of Cnidium officinale exhibits anti-inflammatory effects in BV2 microglial cells by suppressing NF-κB nuclear translocation and the activation of the PI3K/Akt signaling pathway. International Journal of Molecular Medicine, 32, 876-882. https://doi.org/10.3892/ijmm.2013.1447
MLA
Lee, S. H., Lee, J. H., Oh, E. Y., Kim, G., Choi, B. T., Kim, C., Choi, Y. H."Ethanol extract of Cnidium officinale exhibits anti-inflammatory effects in BV2 microglial cells by suppressing NF-κB nuclear translocation and the activation of the PI3K/Akt signaling pathway". International Journal of Molecular Medicine 32.4 (2013): 876-882.
Chicago
Lee, S. H., Lee, J. H., Oh, E. Y., Kim, G., Choi, B. T., Kim, C., Choi, Y. H."Ethanol extract of Cnidium officinale exhibits anti-inflammatory effects in BV2 microglial cells by suppressing NF-κB nuclear translocation and the activation of the PI3K/Akt signaling pathway". International Journal of Molecular Medicine 32, no. 4 (2013): 876-882. https://doi.org/10.3892/ijmm.2013.1447
Copy and paste a formatted citation
x
Spandidos Publications style
Lee SH, Lee JH, Oh EY, Kim G, Choi BT, Kim C and Choi YH: Ethanol extract of Cnidium officinale exhibits anti-inflammatory effects in BV2 microglial cells by suppressing NF-κB nuclear translocation and the activation of the PI3K/Akt signaling pathway. Int J Mol Med 32: 876-882, 2013.
APA
Lee, S.H., Lee, J.H., Oh, E.Y., Kim, G., Choi, B.T., Kim, C., & Choi, Y.H. (2013). Ethanol extract of Cnidium officinale exhibits anti-inflammatory effects in BV2 microglial cells by suppressing NF-κB nuclear translocation and the activation of the PI3K/Akt signaling pathway. International Journal of Molecular Medicine, 32, 876-882. https://doi.org/10.3892/ijmm.2013.1447
MLA
Lee, S. H., Lee, J. H., Oh, E. Y., Kim, G., Choi, B. T., Kim, C., Choi, Y. H."Ethanol extract of Cnidium officinale exhibits anti-inflammatory effects in BV2 microglial cells by suppressing NF-κB nuclear translocation and the activation of the PI3K/Akt signaling pathway". International Journal of Molecular Medicine 32.4 (2013): 876-882.
Chicago
Lee, S. H., Lee, J. H., Oh, E. Y., Kim, G., Choi, B. T., Kim, C., Choi, Y. H."Ethanol extract of Cnidium officinale exhibits anti-inflammatory effects in BV2 microglial cells by suppressing NF-κB nuclear translocation and the activation of the PI3K/Akt signaling pathway". International Journal of Molecular Medicine 32, no. 4 (2013): 876-882. https://doi.org/10.3892/ijmm.2013.1447
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team